The Max Foundation and Cepheid have renewed and expanded their collaboration to increase access to molecular diagnostics in low- and middle-income countries (LMICs).
The agreement provides The Max Foundation with access to Cepheid’s GeneXpert® instruments, offering reduced prices on testing systems, and additional access to test kits indicated for bladder and breast cancer diagnoses.
“Our partnership with The Max Foundation is a natural one, because both Cepheid and The Max Foundation aim to increase patient access to care,” says Scott Campbell, Cepheid SVP and General Manager, Oncology.
Cepheid is a molecular diagnostics company with a mission to improve patient outcomes by enabling access to molecular diagnostic testing for everyone.
Cepheid and The Max Foundation’s collaboration began in 2012, opening access for The Max Foundation to purchase instruments and kits within a preferential pricing agreement. Since 2012, The Max Foundation has brought molecular diagnostic capabilities to more than 20 countries, allowing thousands of patients to access treatment. In the past two years the organization has established a Solidarity Fund, a restricted fund used to purchase diagnostic test kits for the most underserved regions within Max Access Solutions.
The Max Foundation provides access to chronic myeloid leukemia treatment to oncology centers in more than 70 countries and strives to reach thousands of patients with the right treatment at the right time. However, you cannot treat what you cannot diagnose. Patients must have a qualified, molecular diagnostic test in order to gain access to appropriate treatments.
Dr. Eda Cálix, Medical Director in Centro de Cáncer Emma Romero de Callejas in Honduras says prior to the donations, the hospital couldn’t afford the tests. “We had some cases of patients not monitored during a long time (even 11 years), being evaluated only through clinical controls and hematologic results. Our country and our institution really need this support,” she says.
The Max Foundation’s partnership with Cepheid exemplifies how collaborations can solve a growing need for molecular diagnostics to be more accessible and affordable to all.
As Max Access Solutions continues to diversify its treatment portfolio, the team recognizes a growing need for access to diagnostics. The addition of key diagnostics for breast cancer and for bladder cancer provide a unique opportunity for the organization to expand its impact in these disease areas.
The Max Foundation hopes to continue to expand their partnerships with innovators in the diagnostics market in order to increase accessibility and affordability for every person, no matter where they reside.
(For more information on the GeneXpert system, go on Cepheid’s cartridge journey to experience the intricate technology that makes it possible to diagnose patients effectively and efficiently.)
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
The Max Foundation is proud to announce it has signed an expanded collaboration agreement with Bristol-Myers Squibb – a committed pharmaceutical partner and member of our humanitarian pact.
Humanitarian Partnership for Access to Cancer Treatment (PACT) to launch in 5 countries in 2023 providing access to treatment and support for HR+/HER2- advanced breast cancer The Max Foundation, the ABC Global Alliance, the American Society of Clinical Pathology, Cepheid and Novartis AG are joining and committing resources to a unique collaboration Breast cancer is….
The Max Foundation has renewed and expanded its treatment-access agreement with Incyte in Europe. The agreement will now provide treatment access for up to 50 patients in Eastern Europe and Central Asia.
